
    
      This study is PhaseIII clinical trial. According the results of PhaseII study,we find out the
      optimal dose and its maximum effectiveness in relieving the nasal symptoms of eN-LacÂ®
      (Lactobacillus paracasei GMNL-32) in children with PAR.
    
  